Netoglitazone

General description NEK5 or NIMA (never in mitosis gene a)-related kinase 5 is a serine/threonine kinase that is involved in cell cycle regulation. NEK5 has been shown to interact with NEK6 and NEK5 are required for the ibo1/nek6 ectopic outgrowth

General description Nerve growth factor (NGF) is a dimer of 118-residue polypeptide chains linked non-covalently. Both these polypeptides contain three intramolecular disulphide bridges.

General description The nerve growth factor &#946: (NGFB) gene is mapped to human chromosome 1p13.2.

General description The nerve growth factor &#946: (NGFB) gene is mapped to human chromosome 1p13.2.

Antigen: synthetic peptide corresponding to human NF-&kappaB (p65) amino acids 2-17 Host: rabbit Cross-Reactivity: (+) chimpanzee, human, and monkey NF-&kappaB (p65) Application(s): WB The active nuclear form of the NF-&kappaB transcription

Antigen: fusion protein from the C-terminus of the NR2B subunit of rat NMDA receptor Host: rabbit Cross Reactivity: (+) human, rat, and mouse NMDA receptor Application(s): IHC, IP, and WB Overexpression of the NR2B-subunit of the NMDA receptor has

NRC-2694 is an epidermal growth factor receptor ( EGFR ) antagonist with anti-cancer and anti-proliferative properties.In VitroNRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression. MCE has not independently

NRC-2694 is an epidermal growth factor receptor ( EGFR ) antagonist with anti-cancer and anti-proliferative properties.In VitroNRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression. MCE has not independently

NRC-2694 is an epidermal growth factor receptor ( EGFR ) antagonist with anti-cancer and anti-proliferative properties.In VitroNRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression. MCE has not independently

NRC-2694 is an epidermal growth factor receptor ( EGFR ) antagonist with anti-cancer and anti-proliferative properties.In VitroNRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression. MCE has not independently

NS-102 is a selective kainate (GluK2) receptor antagonist. NS-102 is a potent GluR6/7 receptor antagonist .In VitroCombination of NS-102 (10 μM) and GYKI 52466 (30 μM) preventes full loss of compound action potentials (CAPs) during oxygen and

NS-102 is a selective kainate (GluK2) receptor antagonist. NS-102 is a potent GluR6/7 receptor antagonist .In VitroCombination of NS-102 (10 μM) and GYKI 52466 (30 μM) preventes full loss of compound action potentials (CAPs) during oxygen and